Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience

Saved in:
Bibliographic Details
Published in:EJNMMI Research
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864030191526871041
collection WordPress RSS
FRELIP Feed Integration
container_title EJNMMI Research
description
discipline_display Natural Sciences
discipline_facet Natural Sciences
format Online Article
RSS Article
genre Journal Article
id rss_article:19299
institution FRELIP
journal_source_facet EJNMMI Research
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
Biology
Natural Sciences — Life Sciences
Natural Sciences
sub_discipline_display Natural Sciences — Life Sciences
sub_discipline_facet Natural Sciences — Life Sciences
subject_display Biology
Natural Sciences — Life Sciences
Natural Sciences
Biology
Natural Sciences — Life Sciences
Natural Sciences
subject_facet Biology
Natural Sciences — Life Sciences
Natural Sciences
title Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
title_auth Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
title_full Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
title_fullStr Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
title_full_unstemmed Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
title_short Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
title_sort outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷lu]lu-psma-617 radioligand therapy in treatment-refractory mcrpc: preliminary evidence from a pilot experience
topic Biology
Natural Sciences — Life Sciences
Natural Sciences
url https://link.springer.com/article/10.1186/s13550-026-01408-w